Allosteric SHP2 inhibitors such as SHP099 and SHP394 stabilize the closed auto-inhibited state [11, 12], which effectively inhibit the RAS-MAPK signaling pathway in cancer cells driven by epidermal growth factor receptors (EGFR) and other RTKs and their growth in vitro and in vivo [10, 12]. The gene discussed is PTPN11; the disease is cancer.